Search Result

Results for "

splice variant

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Aminoacyl-tRNA Synthetase (1) Androgen Receptor (17) Apoptosis (11) Autophagy (3) c-Met/HGFR (1) Caspase (1) Cytochrome P450 (2) Eukaryotic Initiation Factor (eIF) (1) Fungal (1) Glutaminase (3) Interleukin Related (1) JNK (1) MNK (5) Molecular Glues (5) p38 MAPK (1) PARP (1) Phosphodiesterase (PDE) (1) Prostaglandin Receptor (1) PROTACs (6) Raf (1) Reference Standards (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (23) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (1)

By Targets:

5-HT Receptor (1)

Aminoacyl-tRNA Synthetase (1)

Androgen Receptor (17)

Apoptosis (11)

Autophagy (3)

c-Met/HGFR (1)

Caspase (1)

Cytochrome P450 (2)

Eukaryotic Initiation Factor (eIF) (1)

Fungal (1)

Glutaminase (3)

Interleukin Related (1)

JNK (1)

MNK (5)

Molecular Glues (5)

p38 MAPK (1)

PARP (1)

Phosphodiesterase (PDE) (1)

Prostaglandin Receptor (1)

PROTACs (6)

Raf (1)

Reference Standards (1)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (23)

Inflammation/Immunology (3)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12248

Telaglenastat Maximum Cited Publications 104 Publications Verification CB-839	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .

HY-N1943

Ailanthone 2 Publications Verification Δ13-Dehydrochaparrinone	Androgen Receptor	Inflammation/Immunology Cancer
Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length androgen receptor (AR) (IC₅₀=69 nM) and constitutively active truncated AR splice variants (AR_1-651 IC₅₀=309 nM).

HY-153341

Tagarafdeg CFT1946	PROTACs Raf	Cancer
Tagarafdeg (CFT1946) is an orally active, CRBN-based and mutant-selective bifunctional degradation activating compound (BiDAC) degrader of BRAF ^V600E with a DC₅₀ of 14 nM in A375 cells. Tagarafdeg is capable of degrading BRAF V600E (Class I), G469A (Class II), G466V (Class III) mutations, and the p61-BRAF ^V600E splice variant. Tagarafdeg can be used in tumor research .

HY-70006

Galeterone 3 Publications Verification TOK-001; VN-124-1	Molecular Glues Androgen Receptor MNK Cytochrome P450 Apoptosis	Cancer
Galeterone (TOK-001) is a potent, orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. Galeterone also functions as a CYP17 inhibitor (IC₅₀ = 47 nM). Galeterone induces cell apoptosis. Galeterone inhibits tumor growth in human prostate cancer xenograft mouse models. Galeterone can be used for castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) research ^[1][2].

HY-153918

(R)-SKBG-1 1 Publications Verification	Androgen Receptor	Cancer
(R)-SKBG-1 is a covalent inhibitor targeting the RNA binding protein NONO. (R)-SKBG-1 can reduce the expression of androgen receptor (AR) and its splice variants, inhibiting cancer cell proliferation. (R)-SKBG-1 inhibits androgen receptor expression with IC₅₀ of 3.1 μM and 5.5 μM for AR-FL mRNA and AR-V7 mRNA, respectively. (R)-SKBG-1 interferes with the gene regulatory network of cancer cells and inhibits cancer cell growth by stabilizing the interaction between NONO and mRNA. (R)-SKBG-1 can be used in the study of cancers related to NONO dysfunction, such as prostate cancer .

HY-N15135

Arabinoxylan (Medium viscosity)	Interleukin Related Toll-like Receptor (TLR) Fungal	Metabolic Disease
Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome .

HY-149433

BWA-522	PROTACs Androgen Receptor Apoptosis	Cancer
BWA-522 is an orally active PROTAC degrader targeting full-length androgen receptor (AR-FL) and androgen receptor splice variant 7 (AR-V7). BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor, suppresses AR downstream signaling proteins and induces cancer cells apoptosis. BWA-522 inhibits tumor growth in LNCaP xenograft mouse model. BWA-522 can be used for the research of prostate cancer .

HY-117960

Orismilast LEO-32731	Phosphodiesterase (PDE)	Inflammation/Immunology
Orismilast (LEO-32731) is an orally active and selective PDE4 inhibitor used for the research of inflammatory diseases. Orismilast demonstrates potent inhibition of PDE4B and PDE4D subtype splice variants .

HY-150102

EPI-7170 1 Publications Verification	Androgen Receptor	Cancer
EPI-7170, a ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC) .

HY-117669

VPC-14228	Androgen Receptor	Cancer
VPC-14228 is an inhibitor that selectively targets androgen receptor DNA binding domain (AR-DBD). VPC-14228 inhibits the interaction between AR and DNA, thereby blocking AR-mediated transcriptional activation. VPC-14228 does not rely on nuclear localization inhibition, but rather inhibits the activity of full-length AR and splice variant AR-V7 by interfering with AR binding to chromatin. And VPC-14228 has high selectivity for other nuclear receptors such as ER and PR. VPC-14228 can be used in the study of prostate cancer [2].

HY-160777

VNPP433-3β Galeterone 3β-imidazole	Molecular Glues Androgen Receptor MNK Apoptosis	Cancer
VNPP433-3β (Galeterone 3β-imidazole) is an orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. VNPP433-3β induces cell apoptosis. VNPP433-3β inhibits tumor growth in the CWR22Rv1 xenograft mouse model. VNPP433-3β can be used for the study of castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) .

HY-170329

PROTAC AR Degrader-8	PROTACs Androgen Receptor Apoptosis	Cancer
PROTAC AR Degrader-8 is the PROTAC degrader for androgen receptor (AR) that degrades AR-FL with DC₅₀s of 0.018 μM and 0.14 μM in 22Rv1 cell and LNCaP cell, degrades AR-V7 with DC₅₀ of 0.026 μM in 22Rv1 cell. PROTAC AR Degrader-8 inhibits the proliferation of cancer cell 22Rv1 and LNCaP with IC₅₀ values of 0.038 μM and 1.11 μM. PROTAC AR Degrader-8 arrests cell cycle at G2/M phase, induces apoptosis in 22Rv1 cell. PROTAC AR Degrader-8 exhibits anticancer efficacy in mouse and zebrafish model. PROTAC AR Degrader-8 can be used for the research of prostate cancer, castration-resistant prostate cancer .

HY-P990782

Efzofitimod	Aminoacyl-tRNA Synthetase	Inflammation/Immunology
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .

HY-12248R

Telaglenastat (Standard) CB-839 (Standard)	Glutaminase Autophagy Reference Standards	Cancer
Telaglenastat (Standard) is the analytical standard of Telaglenastat. This product is intended for research and analytical applications. Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .

HY-164552

ZNU-IMB-Z15	Apoptosis Androgen Receptor	Cancer
ZNU-IMB-Z15 (Compound Z15) is an antagonist of the androgen receptor (AR) and also a selective degrader of AR and ARV7. ZNU-IMB-Z15 can directly bind to the ligand-binding domain (LBD) and activation function-1 region of AR, and promote AR degradation through the proteasome pathway. ZNU-IMB-Z15 effectively inhibits the transcriptional activity of AR, AR mutants, and AR splice variants (ARVs), downregulating the mRNA and protein levels of AR downstream target genes, thereby overcoming the resistance to second-generation antiandrogen drugs induced by AR LBD mutations, AR amplification, and ARVs in castration-resistant prostate cancer (CRPC). ZNU-IMB-Z15 can inhibit the proliferation of AR-positive CRPC cell lines and induce their apoptosis, demonstrating anticancer activity both in vivo and in vitro .

HY-176128

BWA-6047	PROTACs Androgen Receptor Apoptosis PARP Caspase	Cancer
BWA-6047 is an oral active PROTAC degrader targeting AR/AR-V7 and GSPT1 with DC₅₀ values of 3.7, 3.0 and 1.2 nM in 22Rv1 cells. BWA-6047 suppresses the expression of AR downstream target genes and and transcriptional activity. BWA-6047 inhibits cancer cells proliferation, causes G1 phase cell cycle arrest and induces apoptosis. BWA-6047 increases cleaved-PARP-1 and cleaved-caspase-3 levels. BWA-6047 reduces growth of LNCaP xenograft tumors in mice models without obvious toxicity. BWA-6047 can be used for the research of prostate cancer .

HY-12248A

Telaglenastat hydrochloride CB-839 hydrochloride	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy and has antitumor activity .

HY-70006A

Galeterone hydrochloride TOK-001 hydrochloride; VN-124-1 hydrochloride	Molecular Glues Androgen Receptor MNK Cytochrome P450 Apoptosis	Cancer
Galeterone (TOK-001) hydrochloride is a potent, orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. Galeterone hydrochloride also functions as a CYP17 inhibitor (IC₅₀ = 47 nM). Galeterone hydrochloride induces cell apoptosis. Galeterone hydrochloride inhibits tumor growth in human prostate cancer xenograft mouse models. Galeterone hydrochloride can be used for castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) research ^[1][2].

HY-177694

PROTAC AR Degrader-11	PROTACs Androgen Receptor	Cancer
PROTAC AR Degrader-11 is a potent androgen receptor and androgen receptor splice variant-7 PROTAC degrader. PROTAC AR Degrader-11 shows potent cytotoxicity against both CWR22RV1 cells and VCaP cells. PROTAC AR Degrader-11 can be used in prostate cancer research . (Structure Note: Pink: Androgen Receptor ligand (HY-171809); Blue: CRBN ligand (HY-A0003); Black: linker (HY-169966))

HY-155812

Tyrosine kinase-IN-6	c-Met/HGFR	Cancer
Tyrosine kinase-IN-6 is a potent and promising RON splice variants inhibitor with anti-cancer and o?antineoplastic effects .

HY-160777B

VNPP433-3β hydrochloride Galeterone 3β-imidazole hydrochloride	Molecular Glues Androgen Receptor MNK Apoptosis	Cancer
VNPP433-3β (Galeterone 3β-imidazole) hydrochloride is an orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. VNPP433-3β hydrochloride induces cell apoptosis. VNPP433-3β hydrochloride inhibits tumor growth in the CWR22Rv1 xenograft mouse model. VNPP433-3β hydrochloride can be used for the study of castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) .

HY-160777A

VNPP433-3β dihydrochloride Galeterone 3β-imidazole dihydrochloride	Molecular Glues Androgen Receptor MNK Apoptosis	Cancer
VNPP433-3β (Galeterone 3β-imidazole) dihydrochloride is an orally active molecular glue degrader, which degrades androgen receptor (AR) and its splice variants (AR-Vs) and MAP kinase-interacting serine/threonine protein kinase Mnk1/2. VNPP433-3β dihydrochloride induces cell apoptosis. VNPP433-3β dihydrochloride inhibits tumor growth in the CWR22Rv1 xenograft mouse model. VNPP433-3β dihydrochloride can be used for the study of castration resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC) .

HY-121249

Capeserod hydrochloride SL65.0155	5-HT Receptor	Neurological Disease
Capeserod hydrochloride (SL65.0155) is a 5-HT_4(e) receptor partial agonist (K_i=0.6 nM) with potent cognitive enhancing properties. Capeserod hydrochloride acts as a partial agonist in cells expressing 5-HT_4(b) and 5-HT_4(e) splice variants, stimulating cAMP production with IC₅₀ values of 244 and 29 nM, respectively. Capeserod hydrochloride is used in the study of memory impairment and dementia .

HY-138844

3-AP-Me	Eukaryotic Initiation Factor (eIF) p38 MAPK JNK Apoptosis	Cancer
3-AP-Me is a dimethyl derivative of the nucleotide reductase inhibitor 3-AP (SML0568). 3-AP-Me can activate the endoplasmic reticulum (ER) stress pathway by promoting the phosphorylation of eIF2α and increasing the gene expression of transcription factors ATF4 and ATF6, leading to cell apoptosis. Additionally, 3-AP-Me can activate the stress kinases c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinases. 3-AP-Me also leads to the upregulation of the spliced mRNA variant XBP1, can be used in cancer research .

HY-403733B

(+)-JJ-450	Androgen Receptor Prostaglandin Receptor	Cancer
(+)-JJ-450 is a non-competitive antagonist targeting the androgen receptor (AR) that inhibits AR nuclear localization and transcriptional activity in the absence of androgen. (+)-JJ-450 is less active than (-)-JJ-450 (HY-403733A) in inhibiting prostate-specific antigen (PSA) expression in LN95 cells, possibly because (+)-JJ-450 targets the ligand binding domain (LBD) of AR. (+)-JJ-450 inhibits the transcriptional activity of AR and its splice variants (e.g., ARv7) by promoting the degradation of unliganded AR in the nucleus and reducing the binding of AR to androgen response elements (AREs). (+)-JJ-450 can be used in castration-resistant prostate cancer (CRPC) studies that are resistant to enzalutamide (MDV3100) (HY-70003) .

HY-403733C

JJ-450	Androgen Receptor	Cancer
JJ-450 is a non-competitive antagonist androgen receptor (AR) that inhibits the transcriptional activity of wild-type AR and mutant AR ^F876L. JJ-450 has an IC₅₀ of approximately 1-10 μM in inhibiting AR transcriptional activity in PC3 cells. It is selective for AR binding and does not compete with androgens for binding to the ligand binding domain (LBD) of AR. JJ-450 inhibits the transcriptional activity of AR and its splice variants (such as AR ^F876L) by inhibiting AR nuclear translocation and promoting the degradation of unliganded AR in the nucleus. JJ-450 can be used in castration-resistant prostate cancer (CRPC) studies that are resistant to Enzalutamide (MDV3100) (HY-70003) .

HY-171808

ITRI-90	Androgen Receptor PROTACs Apoptosis	Cancer
ITRI-90 is an orally active androgen receptor (AR) PROTAC degrader. ITRI-90 effectively degrades both full-length AR (AR-FL) and the splice variant AR-V7 protein via the ubiquitin-proteasome system, thereby inhibiting AR transcriptional activity and the target gene expression. ITRI-90 significantly inhibits the proliferation of prostate cancer cells and induces apoptosis, include Enzalutamide-resistant growth cell. ITRI-90 exhibits favorable pharmacokinetic properties and demonstrates potent antitumor efficacy in vivo. ITRI-90 can be used for prostate cancer research .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990782

Efzofitimod	Aminoacyl-tRNA Synthetase	Inflammation/Immunology
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1943

Ailanthone 2 Publications Verification Δ13-Dehydrochaparrinone	Simaroubaceae Ailanthus altissima (Mill.) Swingle Classification of Application Fields Terpenoids Diterpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	Androgen Receptor
Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length androgen receptor (AR) (IC₅₀=69 nM) and constitutively active truncated AR splice variants (AR_1-651 IC₅₀=309 nM).

HY-N15135

Arabinoxylan (Medium viscosity)	Structural Classification Polysaccharides Antibiotics Leguminosae Pisum sativum Linn Plants Saccharides Other Antibiotics Source Classification	Interleukin Related Toll-like Receptor (TLR) Fungal
Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome .

Host:	Mouse (1) Rabbit (7)
Reactivity:	Human (4) Rat (5) Mouse (8)
Application:	IHC-P (2) ICC/IF (3) mIHC (1) IP (1) WB (7) FC (1) ELISA (2)
Isotype:	IgG (7) IgG1 (1)
Conjugation:	Non-conjugated (8)
Clonality:	Monoclonal (6) Recombinant (3)
Modification:	Unmodified (6)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86957

	MBD1 Antibody (YA6650) CXXC 3 antibody; CXXC-type zinc finger protein 3 antibody; CXXC3 antibody; MBD 1 antibody; Mbd1 antibody; MBD1_HUMAN antibody; MECP1 COMPLEX antibody; Methyl CpG binding domain protein 1 antibody; Methyl CpG binding domain protein 1 isoform PCM1 antibody; Methyl CpG binding protein MBD1 antibody; CXXC 3 antibody; CXXC-type zinc finger protein 3 antibody; CXXC3 antibody; MBD 1 antibody; Mbd1 antibody; MBD1_HUMAN antibody; MECP1 COMPLEX antibody; Methyl CpG binding domain protein 1 antibody; Methyl CpG binding domain protein 1 isoform PCM1 antibody; Methyl CpG binding protein MBD1 antibody; Methyl CpG binding protein splice variant 1 antibody; Methyl CpG binding protein splice variant 2 antibody; Methyl CpG binding protein splice variant 3 antibody; Methyl CpG binding protein splice variant 4 antibody; Methyl-CpG-binding domain protein 1 antibody; Methyl-CpG-binding protein MBD1 antibody; PCM 1 antibody; PCM1 antibody; Protein containing methyl-CpG-binding domain 1 antibody; Regulator of fibroblast growth factor 2 (FGF 2) transcription antibody; RFT antibody; The regulator of fibroblast growth factor 2(FGF 2) transcription antibody;	WB, ICC/IF, FC	Mouse, Rat
	MBD1 Antibody (YA6650) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MBD1.

HY-P86921

	Iba1 Antibody(YA6614) AIF 1 antibody; AIF-1 antibody; Aif1 antibody; AIF1 protein antibody; AIF1_HUMAN antibody; Allograft inflammatory factor 1 antibody; Allograft inflammatory factor 1 splice variant G antibody; allograft inflammatory factor-1 splice variant Hara-1 antibody; balloon angioplasty responsive transcription antibody; BART 1 antibody; AIF 1 antibody; AIF-1 antibody; Aif1 antibody; AIF1 protein antibody; AIF1_HUMAN antibody; Allograft inflammatory factor 1 antibody; Allograft inflammatory factor 1 splice variant G antibody; allograft inflammatory factor-1 splice variant Hara-1 antibody; balloon angioplasty responsive transcription antibody; BART 1 antibody; G1 antibody; G1 putative splice variant of allograft inflamatory factor 1 antibody; IBA 1 antibody; IBA1 antibody; interferon gamma responsive transcript antibody; Interferon responsive transcript 1 antibody; interferon responsive transcript factor 1 antibody; Ionized calcium binding adapter molecule 1 antibody; Ionized calcium-binding adapter molecule 1 antibody; ionized calcium-binding adapter molecule antibody; IRT 1 antibody; IRT1 antibody; Microglia response factor antibody; MRF1 antibody; Protein g1 antibody;	mIHC	Mouse
	Iba1 Antibody(YA6614) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Iba1.

HY-P85890

	Iba1 Antibody (YA5582) AIF 1; AIF-1; Aif1; AIF1 protein; AIF1_HUMAN; Allograft inflammatory factor 1; Allograft inflammatory factor 1 splice variant G; allograft inflammatory factor-1 splice variant Hara-1; balloon angioplasty responsive transcription; BART 1; G1; G1 putative splice variant of allograft inflamatory factor 1; IBA 1; IBA1; interferon gamma responsive transcript; Interferon responsive transcript 1; interferon responsive transcript factor 1; Ionized calcium binding adapter molecule 1; Ionized calcium-binding adapter molecule 1; ionized calcium-binding adapter molecule; IRT 1; IRT1; Microglia response factor; MRF1; Protein g1;	IHC-P, WB, ICC/IF, ELISA	Human, Mouse, Rat
	Iba1 Antibody (YA5582) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Iba1.

HY-P86536

	Iba1 Antibody (YA6228) AIF 1; AIF-1; Aif1; AIF1 protein; AIF1_HUMAN; Allograft inflammatory factor 1; Allograft inflammatory factor 1 splice variant G; allograft inflammatory factor-1 splice variant Hara-1; balloon angioplasty responsive transcription; BART 1; G1; G1 putative splice variant of allograft inflamatory factor 1; IBA 1; IBA1; interferon gamma responsive transcript; Interferon responsive transcript 1; interferon responsive transcript factor 1; Ionized calcium binding adapter molecule 1; Ionized calcium-binding adapter molecule 1; ionized calcium-binding adapter molecule; IRT 1; IRT1; Microglia response factor; MRF1; Protein g1;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Iba1 Antibody (YA6228) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Iba1.

HY-P86692

	AIF1 Antibody (YA6384) AIF 1; AIF1 protein; IBa1; iba-1; IBa 1; allograft inflammatory factor 1; Allograft inflammatory factor 1 splice variant G; balloon angioplasty responsive transcription; BART 1; G1; G1 putative splice variant of allograft inflamatory factor 1; IBA 1; IBA1; interferon gamma responsive transcript; Ionized calcium binding adapter molecule 1; ionized calcium-binding adapter molecule; IRT 1; IRT1; Microglia response factor; MRF1; Protein G1.	WB	Mouse
	AIF1 Antibody (YA6384) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AIF1.

HY-P86692A

	AIF1 Antibody (YA6384)(PBS only) AIF 1; AIF1 protein; IBa1; iba-1; IBa 1; allograft inflammatory factor 1; Allograft inflammatory factor 1 splice variant G; balloon angioplasty responsive transcription; BART 1; G1; G1 putative splice variant of allograft inflamatory factor 1; IBA 1; IBA1; interferon gamma responsive transcript; Ionized calcium binding adapter molecule 1; ionized calcium-binding adapter molecule; IRT 1; IRT1; Microglia response factor; MRF1; Protein G1.	WB	Mouse
	AIF1 Antibody (YA6384) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AIF1.

HY-P80552

	ATF2 Antibody (YA606) Activating transcription factor 2 antibody; Activating transcription factor 2 splice variant ATF2 var2 antibody; ATF 2 antibody; Atf-2 antibody; Atf2 antibody; ATF2 protein antibody; ATF2_HUMAN antibody; cAMP Response Element Binding Protein 2 antibody; cAMP response element binding protein CRE BP1 antibody; cAMP response element-binding protein CRE-BP1 antibody; cAMP responsive element binding protein 2, formerly antibody; cAMP-dependent transcription factor ATF-2 antibody; cAMP-responsive element-binding protein 2 antibody; CRE BP1 antibody; CRE-BP antibody; CREB 2 antibody; CREB-2 antibody; CREB2 antibody; CREBP1 antibody; Cyclic AMP dependent transcription factor ATF 2 antibody; Cyclic AMP-dependent transcription factor ATF-2 antibody; Cyclic AMP-responsive element-binding protein 2 antibody; D130078H02Rik antibody; D18875 antibody; HB 16 antibody; HB16 antibody; Histone acetyltransferase ATF2 antibody; MGC105211 antibody; MGC105222 antibody; MGC111558 antibody; MGC142504 antibody; mXBP antibody; MXBP protein antibody; Tg(Gzma-Klra1)7Wum antibody; TREB 7 antibody; TREB7 antibody	WB	Human, Mouse, Rat
	ATF2 Antibody (YA606) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATF2.

HY-P80552A

	ATF2 Antibody (YA606)(PBS only) Activating transcription factor 2 antibody; Activating transcription factor 2 splice variant ATF2 var2 antibody; ATF 2 antibody; Atf-2 antibody; Atf2 antibody; ATF2 protein antibody; ATF2_HUMAN antibody; cAMP Response Element Binding Protein 2 antibody; cAMP response element binding protein CRE BP1 antibody; cAMP response element-binding protein CRE-BP1 antibody; cAMP responsive element binding protein 2, formerly antibody; cAMP-dependent transcription factor ATF-2 antibody; cAMP-responsive element-binding protein 2 antibody; CRE BP1 antibody; CRE-BP antibody; CREB 2 antibody; CREB-2 antibody; CREB2 antibody; CREBP1 antibody; Cyclic AMP dependent transcription factor ATF 2 antibody; Cyclic AMP-dependent transcription factor ATF-2 antibody; Cyclic AMP-responsive element-binding protein 2 antibody; D130078H02Rik antibody; D18875 antibody; HB 16 antibody; HB16 antibody; Histone acetyltransferase ATF2 antibody; MGC105211 antibody; MGC105222 antibody; MGC111558 antibody; MGC142504 antibody; mXBP antibody; MXBP protein antibody; Tg(Gzma-Klra1)7Wum antibody; TREB 7 antibody; TREB7 antibody	WB	Human, Mouse, Rat
	ATF2 Antibody (YA606) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATF2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks